(Press-News.org) New York, NY — July 17, 2025 — In a major advance for patients with Crohn’s disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of action that is new to inflammatory bowel disease (IBD) treatment, outperformed an established standard of care in promoting intestinal healing and symptom relief.
These findings from two pivotal phase 3 trials known as GALAXI 2 and 3, published today in The Lancet, provided the basis for the recent Food and Drug Administration approval of guselkumab (brand name Tremfya) for the treatment of moderately to severely active Crohn’s disease.
Crohn’s disease affects roughly 780,000 people in the United States and often requires a lifetime of management. Despite numerous available biologic medications, many patients fail to achieve sustained remission. Guselkumab blocks the interleukin-23 (IL-23) pathway, a key driver of chronic intestinal inflammation.
“Suboptimal disease control despite the availability of biologic therapies remains a prevalent problem among patients with Crohn’s disease,” said Bruce E. Sands, MD, MS, the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai and senior author on this paper. “The GALAXI trials were especially impactful as they compared two dosing regimens of guselkumab to both placebo and ustekinumab over a 48-week period. Patients receiving guselkumab showed significantly higher rates of endoscopic healing and deep remission, critical indicators linked to fewer disease flares, hospitalizations, and long-term complications.”
Guselkumab is the first biologic shown in identically designed, 48-week, double-blind trials to outperform another leading biologic—ustekinumab, a monoclonal antibody that blocks both IL-12 and IL-23—for key markers of disease remission and gut healing in Crohn’s disease. The design allowed for head-to-head comparisons to both placebo and ustekinumab. The studies enrolled 1,048 patients worldwide and randomly assigned participants to one of four groups:
guselkumab 200 mg intravenously (IV) at weeks 0/4/8, then guselkumab 100 mg subcutaneously (SC) every eight weeks beginning at week 16
guselkumab IV at weeks 0/4/8, then guselkumab 200 mg every four weeks beginning at week 12
ustekinumab ~6 mg/kg IV at week 0, then ustekinumab 90 mg SC every eight weeks beginning at week 8
placebo
Guselkumab demonstrated statistically significant improvements across multiple endpoints, including endoscopic response and deep remission. Safety outcomes, based on adverse events and laboratory findings, were favorable and consistent with the known profile of guselkumab in approved indications.
Beyond symptom control, the therapy’s corticosteroid-sparing effect further underscores its clinical value, especially for patients seeking alternatives to long-term steroid use.
The GALAXI 2 and 3 trials were sponsored by Johnson & Johnson and enrolled patients with prior biologic treatment failures.
Dr. Sands, the Chief of Mount Sinai’s Dr. Henry D. Janowitz Division of Gastroenterology, is a renowned expert in inflammatory bowel disease. He previously co-authored the pivotal UNITI trial, and was both the lead author and corresponding author on the UNIFI trials. Both of these trials helped establish ustekinumab’s place in IBD care. His latest work builds on that legacy, demonstrating not only the effectiveness of IL-23 inhibition but its potential to redefine front-line treatment.
Link to paper: “Efficacy and safety of intravenous induction and subcutaneous maintenance treatment with guselkumab in participants with Crohn’s disease: results of two phase 3, randomised, double-blind, placebo-controlled, and head-to-head versus ustekinumab, 48-week trials (GALAXI 2 & 3).” Reference: THELANCET-D-24-08019R1
###
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Instagram, LinkedIn, X, and YouTube.
END
As an institution, the U.S. military is the world’s single largest consumer of energy and emitter of climate-altering carbon pollution, on par with the entire nation of Venezuela.
Now for the first time, research by a University of Utah sociologist documented how military spending tracks in near lockstep with emissions. Brett Clark and his coauthors conclude that reducing those expenditures can lead to significant reductions of energy use and, thereby, carbon emissions.
Can the military play a role in climate ...
DALLAS, July 17, 2025 — In light of reports from the White House that President Donald J. Trump has been diagnosed with Chronic Venous Insufficiency (CVI), the American Heart Association is sharing important information on the condition and its association with cardiovascular risk factors, disease and increased risk of death.
According to the Association, the world’s leading nonprofit organization focused on heart and brain health for all, chronic venous insufficiency (a form of chronic venous disease) is highly prevalent - especially in older adults. ...
Gene editing technologies - such as those used in agriculture and de-extinction projects - can be repurposed to offer what an international team of scientists is calling a transformative solution for restoring genetic diversity and saving endangered species.
In a new Nature Reviews Biodiversity Perspective article published today, the authors explore the promises, challenges and ethical considerations of genome engineering, and propose an approach for its implementation into biodiversity conservation.
They argue that gene editing could recover lost genetic diversity in species at risk of extinction using historical samples, such as DNA from museum collections, biobanks ...
Research Highlights:
Scar tissue in the heart may be linked to dangerous heart rhythms in otherwise healthy athletes, according to a U.K. study.
The study, VENTOUX, named after Mont Ventoux—one of the most gruelling climbs in the world-renowned Tour de France cycling race—included about 100 male cyclists and triathletes over age 50.
Embargoed until 6:01 p.m. CT/7:01 p.m. ET, Thursday, July 17, 2025
DALLAS, July 17, 2025 — Scar tissue in the heart was associated with abnormal heart rhythms among healthy, long-time male endurance athletes age 50 or older, potentially increasing ...
When asked to think of a chemical reaction, you might picture bubbling liquids in a beaker, or maybe applying heat to a mixture until something transforms. But some of the most important reactions in nature and industry don’t need heat or solvents. Instead, they need force.
Mechanochemistry is where physical pressure or stress triggers chemical reactions. Imagine molecules being rammed together like bumper cars, or shaken up in a giant cocktail shaker. That shaking and colliding happens every day inside ...
Teeth may seem like static fixtures, but a new collaboration between engineers and clinicians is proving just how dynamic, informative and medically significant our teeth can be.
In a recent study, published in the American Chemical Society’s ACS Applied Materials & Interfaces, engineers and dentists come together to uncover how teeth, as biological material, hold key information for understanding rare craniofacial disorders that develop during childhood. Kyle Vining, Assistant Professor in Materials Science and Engineering (MSE) and in Preventative and Restorative Science at Penn Dental Medicine, leads ...
Most children seeking emergency department (ED) care due to vomiting are discharged home. Although they usually feel better when they leave the ED, the vomiting recurs in nearly one-third of children.
Dr. Stephen Freedman, MD, a pediatric ED physician, led a national study to evaluate if sending children who present for care with frequent vomiting from an acute intestinal infection are better off when provided with an anti-vomiting medication to take, as needed, at home.
“When children are really sick, it’s ...
The Michigan Womyn’s Music Festival, hosted from 1976 to 2015, brought together lesbian feminists for a celebration of culture and activism. Today, the festival is perhaps best known for its controversial "womyn-born-womyn” attendance policy, which excluded trans women from participation. A new article in Signs: Journal of Women and Culture in Society examines the fight for trans inclusion at Michfest and positions it within a rich history of activism at the festival, including antiracist activism by women of color.
In 1991, a woman named Nancy Jean Burkholder was expelled from the Michfest grounds on the basis ...
A newly discovered pathway in a plant process could help farmers grow more successful crops, particularly in places where harsh, high light stresses plants.
The pathway complements the main workflow of photorespiration, indicating photorespiration is more flexible than it seems. Xiaotong Jiang, a post-doctoral fellow in Jianping Hu’s lab at the Michigan State University-Department of Energy Plant Research Laboratory, and colleagues recently published their results in the journal Nature Communications.
Photorespiration ...
In a major step forward for sustainable energy technology, researchers at Worcester Polytechnic Institute (WPI), led by Professor Yan Wang, William B. Smith Professor of Mechanical and Materials Engineering, have developed a new, scalable method to recycle lithium-ion batteries in a way that is both efficient and environmentally friendly.
The team’s research, titled Upcycling Mixed Spent Ni-Lean Cathodes into Ni-Rich Polycrystalline Cathodes, was recently published in Energy Storage Materials, a multidisciplinary peer-reviewed journal focused on the topics of materials and energy. The paper details an innovative hydrometallurgical upcycling approach that offers both environmental ...
